Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Up 423.2% in July

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) saw a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 23,793 shares, an increase of 423.2% from the July 15th total of 4,548 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average trading volume of 127,966 shares, the short-interest ratio is presently 0.2 days.

Institutional Investors Weigh In On Cardio Diagnostics

A number of institutional investors have recently added to or reduced their stakes in CDIO. DRW Securities LLC raised its holdings in shares of Cardio Diagnostics by 122.8% in the 4th quarter. DRW Securities LLC now owns 40,463 shares of the company’s stock worth $110,000 after purchasing an additional 22,298 shares during the period. Citadel Advisors LLC purchased a new stake in shares of Cardio Diagnostics during the 3rd quarter worth about $79,000. Finally, Renaissance Technologies LLC acquired a new stake in Cardio Diagnostics during the 1st quarter worth approximately $30,000. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cardio Diagnostics in a report on Thursday, June 11th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Cardio Diagnostics Stock Up 17.5%

Shares of CDIO traded up $0.32 during mid-day trading on Wednesday, hitting $2.15. The company had a trading volume of 131,779 shares, compared to its average volume of 1,662,314. The business’s 50-day simple moving average is $1.86 and its 200-day simple moving average is $2.14. Cardio Diagnostics has a 1-year low of $0.97 and a 1-year high of $7.91. The stock has a market cap of $6.36 million, a PE ratio of -0.74 and a beta of 2.27.

Cardio Diagnostics (NASDAQ:CDIO) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.51) earnings per share (EPS) for the quarter. The company had revenue of $0.01 million for the quarter. Cardio Diagnostics had a negative net margin of 43,133.33% and a negative return on equity of 80.78%.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.